Zürich (ots) - Im September 2017 bleiben die Angebotsmieten in der Schweiz unverändert. Der Index ...
EvaluatePharma Appoints Alexander Karle as COO
London And Boston (ots/PRNewswire) - EvaluatePharma [http://www.evaluategroup.com](R), the premier source for life science sector analysis and consensus forecasts, has appointed Alexander Karle as Chief Operating Officer. Karle's experience in formulating customer-centric growth strategies and leading them to successful implementation will be instrumental in driving EvaluatePharma's continued expansion within key industry sectors and geographic markets.
Prior to joining EvaluatePharma, Karle served as Vice President of Strategy and Development for global intelligence firm Thomson Reuters. There, he served on the executive leadership team and was responsible for defining and leading the corporate growth strategy for Thomson Reuters' intellectual property and science division, an $800M+ information and services business. Karle also led the restructuring of Thomson Reuters' pharmaceutical benchmarking business, CMR International, where he set strategy and defined new services to integrate with Thomson Reuters' life sciences business. Karle began his professional career as a Senior Associate at Booz Allen & Hamilton. Karle holds a Bachelor of Arts in business, economics and law from the European Business Programme in Mu?nster, Germany and Hull, United Kingdom as well as a Master of Business Administration from Yale University's School of Management.
"Alexander brings a breadth of experience in driving corporate development for global intelligence firms within the life sciences. His expertise in driving successful operational growth for Thomson Reuters' science and healthcare businesses will be incredibly relevant," said Dr. Jonathan de Pass, EvaluatePharma CEO. "We are thrilled to welcome someone of his caliber to our executive leadership team."
Since 1996, EvaluatePharma has been the premier source for life science sector analysis, delivering exclusive, trusted commercial insight into industry performance through its proprietary platform. EvaluatePharma is staffed by a team of over 85 dedicated healthcare analysts employing rigorous methodologies to deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage [http://www.epvantage.com] name support EvaluatePharma's analysis. The EvaluatePharma services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.EvaluatePharma.com.